KSE - Delayed Quote KRW

Shinpoong Pharmaceutical Co.,Ltd (019170.KS)

12,570.00 -500.00 (-3.83%)
At close: 3:30 PM GMT+9
Loading Chart for 019170.KS
DELL
  • Previous Close 13,070.00
  • Open 12,870.00
  • Bid --
  • Ask --
  • Day's Range 12,400.00 - 13,070.00
  • 52 Week Range 9,560.00 - 22,800.00
  • Volume 233,577
  • Avg. Volume 741,532
  • Market Cap (intraday) 643.972B
  • Beta (5Y Monthly) 0.93
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date May 13, 2024 - May 17, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date Dec 29, 2020
  • 1y Target Est --

Shinpoong Pharmaceutical Co.,Ltd, together with its subsidiaries, manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products, as well as antivirals, anticancer drugs, painkillers, anti-inflammatory products, and anthelmintics. It provides active pharmaceutical ingredients; Pyramax, an anti-malarial drug; and drugs for treating hypercholesterolemia, knee osteoarthritis and shoulder periarthritis, and surgical adhesion barrier; prescription drugs; wound dressings; health functional food; and over the counter products. In addition, the company engages in business management and exports its products to approximately 50 countries. The company was founded in 1962 and is headquartered in Seoul, South Korea.

shinpoong.co.kr

--

Full Time Employees

December 31

Fiscal Year Ends

Related News

Performance Overview: 019170.KS

Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

019170.KS
7.03%
KOSPI Composite Index
2.39%

1-Year Return

019170.KS
34.97%
KOSPI Composite Index
0.65%

3-Year Return

019170.KS
87.55%
KOSPI Composite Index
18.98%

5-Year Return

019170.KS
61.09%
KOSPI Composite Index
16.95%

Compare To: 019170.KS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 019170.KS

Valuation Measures

As of 4/18/2024
  • Market Cap

    670.00B

  • Enterprise Value

    656.67B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.34

  • Price/Book (mrq)

    2.50

  • Enterprise Value/Revenue

    3.28

  • Enterprise Value/EBITDA

    -16.49

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -28.63%

  • Return on Assets (ttm)

    -8.33%

  • Return on Equity (ttm)

    -19.04%

  • Revenue (ttm)

    200.23B

  • Net Income Avi to Common (ttm)

    -57.33B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    60.58B

  • Total Debt/Equity (mrq)

    17.04%

  • Levered Free Cash Flow (ttm)

    -26.77B

People Also Watch